摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-2-硝基苯酚 | 17802-02-7

中文名称
3-氯-2-硝基苯酚
中文别名
——
英文名称
3-chloro-2-nitrophenol
英文别名
3-Chlor-2-nitro-phenol
3-氯-2-硝基苯酚化学式
CAS
17802-02-7
化学式
C6H4ClNO3
mdl
——
分子量
173.556
InChiKey
DFMDAJMTLJGKFW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    37.5 °C
  • 沸点:
    250.8±20.0 °C(Predicted)
  • 密度:
    1.554±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    66
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2908999090
  • 包装等级:
    III
  • 危险类别:
    9
  • 危险性防范说明:
    P261,P264,P270,P272,P273,P280,P301+P312+P330,P302+P352,P305+P351+P338+P310,P333+P313,P391,P501
  • 危险品运输编号:
    3077
  • 危险性描述:
    H302,H315,H317,H318,H410
  • 储存条件:
    室温下应保持干燥且密封保存。

SDS

SDS:6905457f6bea7546fc8a457d8e69db68
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Chloro-2-nitrophenol
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-2-nitrophenol
CAS number: 17802-02-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H4ClNO3
Molecular weight: 173.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    CCLXXIX.-的monosulphonated的二硝化米氯酚和磺化和3-氯-2-和-6-硝基苯酚的随后进一步硝化
    摘要:
    DOI:
    10.1039/jr9300002169
  • 作为产物:
    描述:
    3-氯苯酚 在 ammonium nickel(II) sulfate hexahydrate 、 硝酸 作用下, 以 二氯甲烷 为溶剂, 反应 3.0h, 以33%的产率得到3-氯-2-硝基苯酚
    参考文献:
    名称:
    CONDENSED HETEROCYCLIC COMPOUND
    摘要:
    通用式(I)所代表的化合物【其中R1代表C1-6烷基基团、卤素原子或类似物;A代表苯基基团或类似物;X代表—CH(R3)—、—O—、—NH—或类似物;Y代表—O—、—NH—、—N═或—S—;……代表单键或双键;n代表1至3;R2代表C1-6烷基基团、C1-6烷氧基基团或类似物;R3代表氢原子、C1-6烷基基团或类似物】,或其盐,具有降低血液LDL胆固醇作用,并且可用作药物的活性成分。
    公开号:
    US20170298081A1
点击查看最新优质反应信息

文献信息

  • [EN] PYRAZOLE MAGL INHIBITORS<br/>[FR] INHIBITEURS PYRAZOLE DE MAGL
    申请人:ABIDE THERAPEUTICS INC
    公开号:WO2018217805A1
    公开(公告)日:2018-11-29
    Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of monoacylglycerol lipase (MAGL). Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    本文提供了吡唑化合物和包含该化合物的药物组合物。这些化合物和组合物可用作单酰基甘油酶(MAGL)的调节剂。此外,这些化合物和组合物可用于治疗疼痛。
  • [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2009062289A1
    公开(公告)日:2009-05-22
    Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.
    公式I的化合物:其中c、R2、R3、R4、R5、R6、R7和R8按本说明定义,可用作HIV复制的抑制剂。
  • Compounds for treating spinal muscular atrophy
    申请人:PTC Therapeutics Inc.
    公开号:US09617268B2
    公开(公告)日:2017-04-11
    Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.
    本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物和使用方法。在一个具体实施例中,本文提供了一种形式的化合物,可用于调节从SMN2基因转录的mRNA中SMN2的外显子7的包含。在另一个具体实施例中,本文提供了一种形式的化合物,可用于调节从SMN1基因转录的mRNA中SMN1的外显子7的包含。在另一个实施例中,本文提供了一种形式的化合物,可用于调节从SMN1和SMN2基因分别转录的mRNA中SMN1和SMN2的外显子7的包含。
  • [EN] ANTIBIOTIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIBIOTIQUES
    申请人:DISCUVA LTD
    公开号:WO2018037223A1
    公开(公告)日:2018-03-01
    The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.
    本发明涉及公式(I)的抗生素化合物,含有这些化合物的组合物,以及使用这些化合物治疗细菌性疾病和感染的方法。这些化合物在治疗革兰氏阳性和/或革兰氏阴性细菌引起的感染和疾病方面具有应用,特别是在治疗由淋病奈瑟菌引起的感染和疾病方面。
  • PYRAZOLE COMPOUNDS
    申请人:FUKUMOTO Shoji
    公开号:US20100094000A1
    公开(公告)日:2010-04-15
    The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineralocorticoid receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of a disease or condition mediated by the mineralocorticoid receptor activation.
    本发明涉及其中每个符号如规范中定义的。该化合物具有优越的矿物皮质激素受体拮抗作用,并可用作通过矿物皮质激素受体激活介导的疾病或病况的预防或治疗剂。
查看更多